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Cumulative studies during the past 30 years have established the correlation between
opioid abuse and human immunodeficiency virus (HIV) infection. Further studies also
demonstrate that opioid addiction is associated with faster progression to AIDS in
patients. Recently, it was revealed that disruption of gut homeostasis and subsequent
microbial translocation play important roles in pathological activation of the immune
system during HIV infection and contributes to accelerated disease progression.
Similarly, opioids have been shown to modulate gut immunity and induce gut bacterial
translocation. This review will explore the mechanisms by which opioids accelerate
HIV disease progression by disrupting gut homeostasis. Better understanding of these
mechanisms will facilitate the search for new therapeutic interventions to treat HIV
infection especially in opioid abusing population.
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Introduction
Substantial epidemiologic studies report a greater risk of human immunodeﬁciency virus (HIV)
infection in opioid addicts (Nath et al., 2002). Although confounding factors like widespread
use of contaminated needles and nutritional status can contribute to the increased susceptibility
of drug abusers to HIV infection, both clinical and laboratory studies provide strong evidence
that opioid use alone increases risk of HIV infection by modulating the host’s immune function,
enhancing pathogen entry into the immune cells and promoting virus proliferation (Roy et al.,
2011). Opioid users experience more severe neurocognitive disorders than non-drug users, which
are associated with higher levels of systemic inﬂammation (Bell et al., 1998, 2006; Anthony et al.,
2008). However, the clear mechanisms underlying the complex interactions between opioids abuse
and HIV infection still remain largely elusive.
Recent studies focusing on the gastrointestinal (GI) immune system illustrate that the
gut associated lymphoid tissue (GALT) is the primary target of HIV during all stages
of infection (Lackner et al., 2009) and the immunomodulatory eﬀects of opioids on GI
immune system may have consequences in gut defense mechanism and contribute to
accelerated disease progression (Khansari et al., 2013). This review will summarize the
mechanisms by which HIV and opioids modulate GI immunity and disrupt gut homeostasis,
thereby driving pathological immune activation and disease progression following HIV
infection.
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Overview of Gastrointestinal (GI) Immune
System
The GI tract is considered the largest immunologic organ in the
body and plays an important role in maintaining host immune
homeostasis. Maintaining gut homeostasis requires balanced
interactions among specialized epithelial cells, specialized
lymphoid tissues, and commensal bacteria (Mason et al., 2008).
(A) The Structure of Gut Epithelium
The intestinal epithelium is the ﬁrst line of defense in the gut
luminal environment. The well-organized intestinal epithelial
cells not only provide physical barrier preventing potential
pathogen or antigen invasion, but also is integral for nutrient
support and water transport thereby maintaining homeostasis of
the whole organism (Marchiando et al., 2010). The small intestine
is where most chemical digestion and absorption of most of the
nutrients from ingested food takes place. Besides digestion and
absorption, the small intestine is also responsible for immune
surveillance and defense against invading pathogens. To fulﬁll
these multiple functions, the multi-potent stem cells located in
the crypt region diﬀerentiates into four unique epithelial cell
types: (i) absorptive enterocytes, (ii) enteroendocrine cells, (iii)
goblet cells, and (iv) paneth cells (Figure 1; Bullen et al., 2006;
Barker et al., 2007). Absorptive enterocytes and enteroendocrine
cells in the villus are responsible for digestion and absorption.
The goblet cells will migrate to the villus from crypt after
diﬀerentiation and produce large amounts of mucins, which is
the major component of the mucus layer lining the intestinal
epithelium that provides additional protection to the epithelial
barrier (Linden et al., 2008). Paneth cell stays in the base of
the crypt after diﬀerentiation and is the major source of anti-
microbial peptides such as α-defensins. The α-defensins are
cysteine-rich cationic peptides with antimicrobial activity against
a wide range of bacteria and other microbes. Studies of transgenic
and knockout mice have supported a pivotal role of Paneth cell
derived α-defensins for protection against bacterial pathogens
(Porter et al., 2002). Another specialized epithelial cell residing
in the small intestine is the M cell (or microfold cell). M cells are
found in the follicle-associated epithelium overlaying the peyer’s
patches (PPs). Unlike other intestinal epithelial cells, there is no
mucus covering M cells, thus it plays a unique role in antigen
presentation (Mabbott et al., 2013). In addition to the epithelial
cells that have diﬀerentiated from crypt epithelial stem cells,
FIGURE 1 | Structure of gut epithelium. In the small intestine, the epithelial stem cells located in the crypt differentiate into four cell types: the absorptive
enterocytes, enteroendocrine cells, goblet cells, and paneth cells. In the colon, the epithelial stem cells are usually located in the lower parts of gut crypts and the
differentiated cells migrate to the higher position and populate the colonic epithelial surface.
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certain immune cells express tight junctions proteins similarly
to epithelial cells, allowing them to enter between epithelial cells.
These include the dendritic cells and intraepithelial lymphocytes.
In the intestines, dendritic cells can penetrate the epithelium
to actively sample the antigens from the mucus layer (Rescigno
and Di Sabatino, 2009). The intraepithelial lymphocytes are
mainly involved in insuring the integrity of gut epithelium and
maintaining the balance between normal immune responses and
excessive inﬂammation (Cheroutre, 2005).
The major function of the colon is reabsorption of water and
any remaining soluble nutrients from the food. The lack of villi
in the colon results in a much smaller surface area compared to
the small intestine. Organizationally, the epithelial stem cells are
located in the lower parts of gut crypts and the diﬀerentiated cells
migrate to the apical position and populate the colonic epithelial
surface (Barker et al., 2007).
To avoid para-cellular leak of bacteria from gut lumen, the
intercellular junctions known as tight junctions join adjacent
cells together by extending from the cytoskeleton proteins of
one cell into the extracellular matrix, ﬁnally joining with the
tight junction proteins of another cell (Anderson and Van
Itallie, 2009). Tight junction proteins are able to allow the
transport of small solutes, water, and some macromolecules
through the para-cellular pathway selectively and exclude the
potentially harmful molecules. Tight junction proteins in the
intestinal epithelium include transmembrane proteins belonging
to the occludin and claudin families. These proteins seal the
para-cellular pathway between the epithelial cells. In addition
to transmembrane molecules, the para-cellular proteins include
zona occludens-1 (ZO-1) and zona occludens-2 (ZO-2). They
play an important role in supporting the organization of tight
junction proteins (Peterson and Artis, 2014). The permeability
of tight junction is dynamic and determined by the isoforms,
quantity, and organizations of these proteins. Disruption of
gut tight junction protein results in barrier defects and is
associated with various intestinal diseases. For example, the
genetic polymorphisms of the tight junction protein have been
linked to celiac disease, ulcerative colitis, and Crohn’s disease
(Schulzke et al., 2009).
(B) Immune Cells in GALT, Mesenteric Lymph
Node (MLN), and Lamina Propria
Diﬀerent types of immune cells are distributed in GALT like
PPs and isolated lymphoid follicles, mesenteric lymph node
(MLN), and the lamina propria. The major immune cell
population within gut tissues includes macrophages, dendritic
cells, mucosal mast cells, neutrophilic granulocyte, eosinophilic
granulocyte, T lymphocytes, and plasma cells (Figure 2).
These cells can modulate the intestinal microenvironment by
secreting antibodies, cytokines, or chemokines as well as mediate
interaction with the enteric nervous system (ENS).
In both humans and rodents, PPs are organized lymphoid
nodules usually found in the ileum and less frequently in
the jejunum. PPs are usually covered by follicle-associated
epithelium, which contains special M cell. M cell can sample
antigen directly from the gut lumen and deliver it to antigen-
presenting cells like dendritic cells. T cells, B cells, and memory
FIGURE 2 | Immune cells in gastrointestinal (GI) tract. The major immune
cell population within gut tissues includes macrophages, dendritic cells,
neutrophilic granulocyte, T lymphocytes, and B lymphocytes. The Peyer’s
patches in the small intestine and the isolated lymphoid follicle in the colon are
composed of dendritic cells, B cells and T cells, which are crucial for antigen
presentation from gut lumen. Antigen presenting cells (APCs) migrate to the
mesenteric lymph node (MLN) through afferent lymphatic system. By receiving
the signals presented by APCs, MLN amplify the immune responses. Lamina
propria T cells have the characteristics of activated effector lymphocytes. The
major populations of T cells residing in lamina propria are the CD4+ T cells,
predominated by Th1 and Th17 population.
cells in PPs are stimulated upon encountering antigen. These
cells migrate to the MLN through aﬀerent lymphatic system. By
receiving the signals presented by dendritic cells, MLN amplify
the immune responses. In this way, MLN plays a key role in
tolerance induction to food proteins and in host defense against
the pathogens from the gut lumen (Mason et al., 2008). PPs
are not present in the colon. Isolated lymphoid follicles provide
immune surveillance and protection against potential pathogen
instead of PPs (Koboziev et al., 2010; Suzuki et al., 2010; Lycke
and Bemark, 2012).
Within the lamina propria, immune cells constantly monitor
for abnormalities both in the intestinal lumen as well as inside
host GI tissue. Antigen presenting cells (APCs) includes dendritic
cells, macrophages, and neutrophils. These cells recognize
antigens from the gut lumen and present them to adaptive
lymphocytes (T cells and B cells) to initiate the immune
responses. Various cytokines and chemokines produced by
these APCs are also involved in the regulation of intestinal
inﬂammation (Farache et al., 2013). Most lamina propria T
cells have the characteristics of activated eﬀector lymphocytes.
The major populations of these T cells are the CD4+ T Cells,
predominated by Th1 and Th17 population. Th1 cells produce
IFN-γ, a cytokine important for the control of virus infection and
responsible for the pathogenesis of inﬂammatory bowel disease.
Th17 cells produce Th17 cytokines including interleukin (IL)-
17A, IL-17F, and IL-22 (Shale et al., 2013). The role of Th17
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cytokines in host defense against extracellular pathogens will
be discussed in the following part. IgA+ plasma cells are the
dominant population in the lamina propria. The secretory IgA
produced by plasma cells can neutralize toxins and mediate
ingestion of pathogen via opsonization (Suzuki et al., 2010).
Taken together, both adaptive and innate immune cells are
collectively important for maintaining homeostasis within the
GI tract. Disruption of any cellular component may potentially
predispose hosts to infections or initiate an abnormal immune
response that accelerates disease progression.
(C) Gut Microbiota in Gut Immunity
Gut commensal microbiota is an essential compartment of
the gut immune system playing a critical role in maintaining
intestinal homeostasis. The gut microbiome is responsible for
the breakdown of complex nutrients that the host cannot digest
and metabolize toxic xenobiotic agents into harmless metabolite
(Tremaroli and Bäckhed, 2012). They are also able to exclude
potential pathogens in the gut lumen (Sekirov et al., 2010).
Secondly, they are involved in formation of mucus layer outside
the epithelium. Previous studies have shown that microbial ﬂora
inﬂuences the number of goblet cells, their mucin production,
and the glycosylation of mucins (Gaskins, 2001). Moreover, they
are essential for the development of lymphoid tissues like PPs
and are able to modulate T cell and B cell responses (Lee and
Mazmanian, 2010). For example, most commensal bacteria have
no direct contact with intestinal epithelial cells except for the
segmented ﬁlamentous bacteria (SFB), which are able to adhere to
epithelial cells especially to those in the PPs. Interestingly, recent
studies show that the mice without SFB have signiﬁcantly less IL-
17 production in their intestines, implying the important role of
SFB in Th17 diﬀerentiation (Ivanov et al., 2009). Not surprisingly,
lack of gut commensal microbiota will result in abnormalities
such as increased susceptibility to infectious diseases. For
example, germ-free mice, which lack microbial colonization,
show increased susceptibility to Salmonella due to impaired
IgA production and diminished T cell response (Hapfelmeier
et al., 2010). The germ-free mice also lack inﬂammatory CD4+
T-helper cells as well as regulatory T cells (Tregs; Strauch et al.,
2005; Niess et al., 2008).
HIV-Mediated Disruption of Gut
Homeostasis
The mucosal tissues are primary sites of viral transmission and
the major sites for viral replication and CD4+ T cell destruction.
With the largest mucosal surface, the GI tract is targeted during
all stages of HIV infection and plays a central role in the
pathogenesis of AIDS.
(A) Compromised GI Epithelial Barrier Function
and AIDS Pathogenesis
Cumulative studies have demonstrated that HIV infection exerts
a negative impact on intestinal structure and function that
begins early in infection and might favor disease progression via
microbial translocation and generalized immune activation.
One of the mechanisms contributing to compromised
intestinal epithelial integrity is the deﬁciency of epitheliotropic
factors, which are required for epithelial cell growth,
maintenance, and renewal. Elevated levels of apoptosis-
related gene expression like caspase-3 are observed in epithelial
cells while genes involved in epithelial diﬀerentiation pathways
like casein kinase 2A1 and Wnt 5A are down-regulated during
primary HIV infection (Sankaran et al., 2008), supporting that
the maintenance and renewal mechanisms of gut epithelial cells
are impaired following HIV infection.
Human immunodeﬁciency virus has also been shown to
modulate the tight junctions between both endothelial and
epithelial cells (Mahajan et al., 2008; Estes et al., 2010). HIV has
been shown to modulate tight junctions by disrupting CD4+ T
cells, which typically support the maintenance of tight junctions
(Shanahan, 1999). However, studies have also shown that HIV
proteins such as Tat (transactivator of transcription) and GP120
can directly disrupt tight junctions on epithelial cells in culture
(Bai et al., 2008; Nazli et al., 2010). This may be the mechanism in
early pathogenesis for how bacterial translocation gets initiated to
start a vicious cycle of immune activation and infection in the GI
tract. Further studies indicate that increases in proinﬂammatory
cytokine production in the intestines may be involved in tight
junction modulation as well. Up-regulation of proinﬂammatory
cytokine in the colon as early as 2.5 days following SIV infection
(Hirao et al., 2014) and in the intestine of HIV-infected patients
(McGowan et al., 2004; Sankaran et al., 2005) could facilitate
mucosal damage by activating myosin light chain kinase (MLCK;
Turner, 2006).
As discussed above, the epithelial barrier in the GI tract is
crucial in maintaining a sterile barrier between the lumen of
the intestine and the host. The central role of gut epithelial
barrier in the disease progression following SIV infection
has been investigated using African green monkeys and the
sooty mangabey (Gordon et al., 2007; Pandrea et al., 2007;
Silvestri et al., 2007; Klatt et al., 2012) Despite high viral
loads there is no disease progression to AIDS in these animals
although the infection induces a rapid loss of intestinal CD4+
T cells, which is similar to what has been observed in HIV-
infected humans and SIV-infected macaques. In contrast to
the persistent immune activation in HIV-infected humans and
SIV-infected macaques, the attenuated immune activation may
explain the non-progressive SIV infection in African Non-
human Primates. Moreover, the immune activation is usually
associated with compromised GI integrity and subsequent
microbial translocation (Klatt et al., 2010). All these data suggest
that the microbial translocation from the leaky gut plays a
determinant role in disease progression following SIV infection.
(B) Immune Cells in Disease Progression
During HIV Infection
Recent studies demonstrate that CCR5+CD4+ memory T cells
are primary targets for HIV/SIV (Okoye and Picker, 2013). And
the gut lamina propria contains a much larger percentage of
mucosal CCR5+CD4+ memory T cells compared to peripheral
lymphoid tissues, which may explain why the GI tract is a
major site of CD4+ T cell depletion and viral replication in
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HIV/SIV infection (Zeitz et al., 1988; Veazey et al., 1998).
HIV/SIV infection causes rapid depletion of CCR5+CD4+ T
cells by 21 days after infection and most infected cells in the
intestine are present in immune inductive sites (Veazey et al.,
1998, 2000, 2001). The early loss of CD4+ T cells in the gut
following HIV/SIV infection contributes to the disruption in
normal intestinal epithelial barrier function as discussed in the
previous section, resulting in systemic translocation of bacterial
products (Brenchley et al., 2006).
Speciﬁcally, CD4+ Th17 cells have been shown to play an
important role in mediating the pathogenesis of AIDS following
infection, as studies comparing pathogenic and non-pathogenic
SIV infection have shown a preferential loss of these cells in
pathogenic infections (Brenchley et al., 2008; Cecchinato et al.,
2008; Peng et al., 2013). Th17 cells produce IL-17 and IL-22
instead of interferon gamma or IL-4. These cells play a unique
role in maintaining intestinal homeostasis and production of
antimicrobial defensins (Monteleone et al., 2010; Rubino et al.,
2012; Gu et al., 2013). Therefore, the loss of Th17 cell in gut may
provide a potential mechanism for gut barrier dysfunction and
microbial translocation.
Following microbial translocation, some of the microbial
products have been shown to activate immune cells, leading to
localized cytokine production and activation of other immune
cells such as CD4+ T cells thereby providing new substrates for
HIV/SIV replication. The proinﬂammatory cytokine produced
by the activated immune cells further compromise the intestinal
epithelial barrier function. For example, IL-1β produced by
the paneth cells in the crypt is responsible for gut barrier
disruption following SIV infection (Hirao et al., 2014). Besides
promoting gut barrier dysfunction and intestinal inﬂammation,
the proinﬂammatory cytokine IL-6 can also promote viral
replication. A recent study by Mohan et al. (2008) show that
IL-6 induces a signiﬁcant increase in the expression levels of
CCAAT/Enhancer Binding Protein (C/EBP)-β following SIV
infection. C/EBP-β binds to the long terminal repeat (LTR) of
HIV and SIV in the infected cells of gut lamia propria, facilitating
both viral replication and intestinal inﬂammation (Mohan et al.,
2008).
(C) HIV-Induced Dysbiosis in the Gut
Microbiome
More recently, evidence suggests that disease progression
following HIV/SIV infection is associated with dysbiosis in the
microbiome of infected patients at multiple sites. In areas where
opportunistic infections take place, such as the lingual cavity,
the microbiome has been suggested to become more pathogenic
(Dang et al., 2012). Within the GI tract, microbial populations
such as proteobacteria species, Prevotella, and Enterobacteriaceae
have been shown to be correlated with increase immune
activation and increased in abundance in HIV patients (Dillon
et al., 2014; Mutlu et al., 2014). Interestingly, species of
Proteobacteria have been identiﬁed in the brains of HIV-infected
patients (Branton et al., 2013), which is likely a cumulative result
of microbial dysbiosis and disruption of tight junctions especially
in the blood brain barrier. Certain strains have also been
correlated with better health in HIV patients. For instance, high
abundance of Lactobacillales have been shown to be protective
of CD4+ T cell loss and microbial translocation (Pérez-Santiago
et al., 2013). Metabolic changes have also been correlated to
microbial dysbiosis (Vujkovic-Cvijin et al., 2013). These changes
are likely a result of prolonged immune activation characteristic
of HIV patients and exacerbate dysfunction within the GI tract.
Additionally, most recent study using SIVmodels suggest that the
administration of antiretrovirals induces substantial microbiome
dysbiosis in the GI tract while virus alone shows only modest
eﬀects on the gut microbiome (Klase et al., 2015). Therefore,
more studies are needed to better understand how HIV and/or
antiviral therapy modulate gut microbiota and how dysbiosis in
the gut microbiome correlate with infection and contribute to the
pathogenesis of AIDS.
GI Disorders Associated with Opioid
Abuse
(A) Opioid Receptor Distribution in Gut
Opioids exerts their actions by binding to several subtypes of
opioid receptors, including (i) μ-receptors, (ii) δ-receptors, (iii)
κ-receptors, and (iv) non-classical opioid receptors (Waldhoer
et al., 2004). Originally, opioid receptors were thought to be
expressed only in the central nervous system. However, a wealth
of literature now provides evidence that opioid receptors are
also expressed in peripheral tissues such as the GI tract. Several
groups have attempted to characterize opioid receptor expression
in peripheral tissues using quantitative real-time RT-PCR. Their
results showed that allμ-, δ-, and κ-receptors have low expression
levels in the small intestine (Peng et al., 2012). Using a similar
approach in rats further validated the occurrence of μ-, δ-, and
κ-receptors in both small and large intestine (Wittert et al., 1996).
In gut tissues, opioid receptors are mainly expressed in the ENS,
which is comprised of the myenteric and submucosal plexus. By
binding to the opioid receptors in the ENS, various endogenous
and exogenous opioids are able to modulate GI motility and
secretion. Besides ENS, opioid receptors expressed on immune
cells have been shown to play a role in intestinal inﬂammation
(McCarthy et al., 2001; Philippe et al., 2003). Interestingly, it has
been reported that enterocytes isolated from the crypt epithelium
of guinea pigs have both μ- and δ- opioid receptors (Lang
et al., 1996). Opioid receptor expression in intestinal epithelial
cells is further supported by Rousseaux et al.’s (2007) study, in
which they show that opioid receptors in intestinal epithelial cells
could be up-regulated by lactobacillus, which may provide novel
approaches for the treatment of abdominal pain.
By activating these opioid receptors in intestinal tissues
(Figure 3), opioids exert both pharmacological and adverse
eﬀects in the gut, including alleviating abdominal pain,
modulating GI motility, and suppressing intestinal immune
functions.
(B) Adverse GI Effects Associated with Opioid
Use
Themajor adverse GI symptoms in opioid abuser include nausea,
vomiting, constipation, and bloating (Figure 4; Miaskowski,
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FIGURE 3 | Opioid receptor distribution in intestines. Opioid receptors are not only expressed on neutrons in the myenteric plexus and submucosal plexus,
which are involved in modulating gut motility and secretion but are also expressed on intestinal epithelial cells and immune cells, implying that opioids could impact
the gut barrier function and immune responses as well.
2009; Tuteja et al., 2010; Khansari et al., 2013). Nausea and
vomiting are one of the common side eﬀects associated with
opioid analgesics. Multiple mechanisms are involved in opioid-
induced nausea and vomiting, including direct stimulation of the
chemoreceptor trigger zone (CTZ) for vomiting, inhibition of
gut motility, and stimulation of the vestibular apparatus. Opioids
are small molecules, which can cross blood–brain barrier and
stimulate CTZ via the activation of μ- and δ-receptors. Opioid
inhibition of gut motility results in gut distension, extended
GI emptying time, and constipation, which stimulates visceral
mechanoreceptors and chemoreceptors to induce nausea and
vomiting. Other studies suggest that opioids bind to μ-receptors
in the vestibular apparatus directly and the stimulation of
vestibular apparatus results in nausea and vomiting (Porreca and
Ossipov, 2009).
Another adverse symptom associated with opioid treatment
is a decrease in GI motility. The normal motor functions
of the GI tract are crucial for mixing and propelling food
particles at rates that allow absorption of nutrients, cleaning the
proximal intestine of residual food and bacteria, and enabling
mass movement. Thus, the bowel dysfunction induced by
opioid treatment may lead to serious consequences in patients
(Ukleja, 2010). There are multiple mechanisms contributing
to opioid-induced decreased GI motility: Opioids are able
to interact with the opioid receptors on presynaptic nerve
terminals in the myenteric plexus to initiate signals that increase
intestinal resting tone to the point of spasm while decreasing
propulsive peristaltic waves.Moreover, by binding toμ-receptors
within the ENS, opioids treatment increase activity of the
sympathetic nervous system and inhibit vasoactive intestinal
peptide release thus aﬀecting gut secretion and absorption. The
overall decreased gut secretion causes a delay in digestion,
increased water and sodium reabsorption and formation of dryer
and harder stools, which can contribute to prolonged transit of
the intestinal contents through the GI tract. There are two major
types of GI motility disorder limiting the clinical application
of opioids: postoperative ileus and constipation (Miaskowski,
2009). Constipation is the major GI motility disorder occurring
with chronic opioid treatment. Although laxatives or opioid
antagonists can alleviate constipation, their eﬃcacy is still
insuﬃcient (Tuteja et al., 2010). The disrupted GI motility may
contribute to increased susceptibility to infections with gut origin
considering that impaired peristalsis results in accumulation of
residual food and bacteria in the gut lumen. Clinical studies
imply that the early enteral feeding could enhance immune
function and decrease the risk of infections in postoperative
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FIGURE 4 | Adverse GI effects associated with opioid administration.
(A) Opioid treatment induces nausea and vomiting via chemoreceptor
trigger zone (CTZ) stimulation, vestibular stimulation, and GI motility
inhibition. (B) Opioid treatment induces GI motility disturbances by
decreasing propulsive peristaltic waves, inhibiting GI secretion and
modulating gut microbiome. (C) Opioid treatment disrupts gut homeostasis
by influencing gut epithelial cells and immune cells directly or by inhibiting
GI motility.
patients, so delayed enteral feeding because of opioid treatment
and subsequent ileus may be responsible for increased risk of
infection. Additionally, the opioid loperamide has been shown
to shift microbiome taxonomic and metabolic proﬁle, and these
changes contribute to development of constipation in mice
(Touw et al., 2014). As discussed previously, the dysbiosis in the
gut microbiome plays a crucial role in GI homeostasis disruption
and promotes pathogenesis of gut infectious diseases especially
for HIV infection. Thus it will be interesting to investigate how
opioids and/or opioid-induced GI motility disorder inﬂuence
gut microbiome and the physiological consequence of this
modulation.
Despite the observation that opioid receptors are expressed
on immune cells within the intestinal lamina propria, studies
focusing on the eﬀects of opioids on intestinal immune function
and inﬂammation are relatively sparse. Researches using animal
models show that both chronic morphine and morphine
withdrawal can lower host defense to enteric bacteria such as
Salmonella enterica, Acinetobacter baumannii, and Pseudomonas
aeruginosa. Opioids can induce bacterial translocation into the
systemic system resulting in sepsis in mice (Hilburger et al.,
1997; Ocasio et al., 2004; Feng et al., 2006; Breslow et al.,
2011; Babrowski et al., 2012; Meng et al., 2013). In addition
to bacterial translocation, morphine has been documented to
increase pro-inﬂammatory cytokine production in rats and
accelerate the progression of LPS-induced sepsis to septic shock
(Roy et al., 1999; Greeneltch et al., 2004; Ocasio et al., 2004).
In clinical studies, higher circulating morphine levels were
observed in patients with sepsis, severe sepsis, and septic shock
compared with healthy controls, implying the role of opioids
in sepsis progression (Glattard et al., 2010). Overall, both
clinical and laboratory studies provide evidence that besides
the indirect eﬀects mediated by GI peristalsis, other direct
eﬀects of opioids on epithelial cells and immune cells on
intestinal lamina propria and GALTs also play important roles
in impaired gut immune function. However, the mechanisms
underlying compromised gut immune function and increased
susceptibility to infections after opioid treatment have not been
well studied.
Opioids Promotes HIV Progression by
Disrupting Gut Homeostasis
Chronic opioid abuse is of particular public health concern
for the spread of infectious diseases, especially in the context
of the HIV epidemic. In certain regions, up to 40% of
HIV infected individuals are believed to abuse opioids (UN
Joint Programme on HIV/AIDS (UNAIDS), 2013). Opioid
users also suﬀer from a faster progression of infection to
AIDS, as well as severe long term consequences such as
neurocognitive defects in both humans and non-human primate
models studied (Kapadia et al., 2005; Rivera-Amill et al.,
2010; Byrd et al., 2011). Studies using peripherally acting
μ-opioid receptor antagonist methylnaltrexone indicate that
opioids can increase the infectivity of cells and viremia, which
are mediated by the peripheral μ-opioid receptors (Ho et al.,
2003).
Most recent studies have focused on how opioid abuse
promotes neurocognitive dysfunction like HIV-associated
neurocognitive disorders (HAND) in the infected individuals. All
these studies consistently showed that opioid abusers experience
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FIGURE 5 | Both human immunodeficiency virus (HIV) infection and
opioid abuse induce disruption of gut homeostasis. (A) Opioids and HIV
infection can induce intestinal barrier disruption and subsequent microbial
translocation. (B) Opioids and HIV infection can induce an abnormal
inflammatory response in the gut. (C) Opioids and HIV infection has been shown
to induce dysbiosis in the gut microbiome.
more severe neurocognitive defects including HIV-associated
dementia (Bell et al., 1998, 2006). Further mechanistic studies
correlate the increased neurotoxicity of HIV in opioid abusers
with up-regulated inﬂammation (Gurwell et al., 2001; El-Hage
et al., 2008; Bokhari et al., 2009).
However, the eﬀects of opioid abuse on GI homeostasis during
HIV infection are not well studied although both opioids and
HIV have been shown to disrupt the intestinal homeostasis
through the similar pathways (Figure 5). As previously described,
both HIV/SIV infection and morphine treatment can induce
the intestinal epithelial barrier damage. Indeed, humans infected
with HIV who use heroin have been shown to have greater
amounts of LPS in their serum compared with non-users
(Ancuta et al., 2008), implying that disruption of barrier function
within the gut is more severe in drug using HIV patients.
An investigation of gut biopsy from HIV-infected patients
displays microtubule depolymerization, which is expected to
be associated with intestinal tight junction disorganization
and as a result of MLCK activation (Clayton et al., 2001;
Turner, 2006). Interestingly, our study also shows that morphine
treatment alone induces intestinal tight junction disruption and
bacterial translocation by activating MLCK (Meng et al., 2013).
Therefore, it is conceivable that opioids and HIV infection
either synergistically or additively modulate MLCK activation
explaining the more sever gut barrier dysfunction observed
in drug abusing HIV infected patients. This was recently
validated by our studies where it was demonstrated that opioids
exacerbated HIV induced gut barrier disruption, increased
bacterial translocation from the gut lumen, and sustained
systemic inﬂammation with an increase in both IL-6 and TNF-α
using a rodents model of HIV (Sindberg et al., 2014).
In addition to gut barrier damage, both HIV infection and
opioid abuse have been shown to aﬀect the functions of gut
immune cells, resulting in abnormal immune activation in the
gut and accelerated disease progression. Chronic morphine has
been implicated to modulate populations and activities of Tregs
and Th17 cells. The T cell populations with surface markers
characteristic of gut-homing (CD161 and CCR6) and HIV-1
susceptibility (CCR5 and α4β7 integrin) were also increased
in morphine-treated animals (Cornwell et al., 2013). Recent
reports indicate that integrin α4β7 binds to HIV-1 gp120,
together with CD4 and CCR5, forms a complex with the viral
envelope glycoprotein, which promotes cell–cell spreading of
HIV-1 (Piguet and Sattentau, 2004; Arthos et al., 2008). On basis
of this data, it is reasonable to speculate that opioid abuse will
enhance HIV replication and spread in the gut, which contributes
to accelerated disease progression in opioid abuser.
Conclusion
Cumulative studies focusing on gut homeostasis help us
recognize the central role of gut mucosal tissues in the
pathogenesis of AIDS following HIV infection. Virus infection
can induce compromised gut epithelial barrier function,
abnormal immune activation within the gut tissues, and the
dysbiosis in the gut microbiome, which in turn facilitates HIV
replication and the disease progression.
Additionally, more recent studies demonstrate that opioid
abuse can disrupt gut homeostasis in the HIV-infected
individuals. The severe disruption of gut homeostasis observed
with opioids and models of HIV infection supports what is
observed in the clinical studies as HIV patients who inject
opioids have higher levels of bacterial translocation than
patients who do not use opioids, which is likely why HIV
patients who abuse opioids have more severe pathogenesis of
HIV and develop AIDS much more quickly than non-users.
However, the molecular mechanisms underlying the interactions
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of opioid abuse and HIV-induced enterotoxicity are still not
well understood. Better understanding of these mechanisms
may allow for therapeutic interventions to prevent or slow
the pathogenesis in the gut following HIV infection, which
will ﬁnally lead to more powerful strategy to control HIV
disease progression especially in the opioid using and abusing
population.
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